Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Section 5 of 6

Economic information and modeling report

25 evidence topics · 39 sources

Modeling overview

Summary: price of darovasertib and drug cost inputs for the regimen and its comparators

No price, wholesale acquisition cost, budget impact model, or cost-effectiveness analysis of darovasertib or of the darovasertib plus crizotinib regimen was found. IDEAYA states that darovasertib, if approved for one or more designated indications, “may also be excluded from certain mandatory price negotiation provisions of the 2022 Inflation Reduction Act”.

  • Crizotinib: Pfizer lists the wholesale acquisition cost of XALKORI at $23,773.10 per package of 60 capsules for both the 200 mg and 250 mg strengths, as Pfizer's published list price before any discount or rebate, accurate as of March 10, 2026. OptimUM-02 gives crizotinib 200 mg twice daily with darovasertib 300 mg twice daily; the XALKORI label's recommended dosage for ALK- or ROS1-positive metastatic NSCLC is 250 mg twice daily, with 200 mg twice daily as the first dose reduction. In OptimUM-02, median relative dose intensities were 91.0% for darovasertib and 77.1% for crizotinib, and median duration of treatment was 6.31 months.
  • Tebentafusp: Immunocore lists KIMMTRAK 100 mcg/0.5 mL vial (NDC 80446-0401-01) at a wholesale acquisition cost of $22,050.00, effective 1 July 2026. The label dose is 20 mcg on Day 1, 30 mcg on Day 8, and 68 mcg on Day 15 and once every week thereafter, intravenously, until unacceptable toxicity or disease progression. CADTH notes that “Drug wastage is quite significant” because the standard dose is less than the vial size (68 mcg vs 100 mcg). Under the 2024 physician fee schedule, CMS granted KIMMTRAK an applicable percentage of unused or discarded product volume subject to refund of 45%, and Immunocore does not currently expect to make refund payments under the CMS Rule. Immunocore reports KIMMTRAK net revenue of $257.0 million in the United States for 2025.
  • Pembrolizumab: Merck lists KEYTRUDA at $12,517.44 per dose given every 3 weeks and $25,034.88 per dose given every 6 weeks, current as of September 2026; the melanoma dose is 200 mg every 3 weeks or 400 mg every 6 weeks.
  • No manufacturer-published U.S. list price of nivolumab, ipilimumab, dacarbazine, or the HEPZATO KIT was found. In the OptimUM-02 control arm, ipilimumab plus nivolumab was selected for 79 participants (76.7%) and pembrolizumab for 24, and no participant received dacarbazine; the topline release gives 76% (n=78) and 24% (n=25). Median duration of treatment was 2.87, 2.56, and 2.79 months for pembrolizumab, ipilimumab, and nivolumab.
  • In Germany, the G-BA lists annual treatment costs per patient after statutory rebates of €605,881.61 to €619,990.00 for tebentafusp, €65,157.24 for ipilimumab, €75,915.32 to €76,207.30 for nivolumab, and €4,694.71 to €12,497.72 for dacarbazine.

Summary: eligible population inputs

  • Incidence of uveal melanoma: IDEAYA estimates an annual incidence of primary uveal melanoma of more than 3,000 patients in the United States and more than 10,000 globally. Castle Biosciences estimates approximately 2,000 patients diagnosed annually with uveal melanoma in the United States. The American Cancer Society estimates about 3,200 new cancers of the eye and orbit, mainly melanomas, in the United States in 2026. In the United States from 1975 to 2020, the mean age-adjusted incidence of primary uveal melanoma was 5.6 per million population (95% CI, 5.5 to 5.7); the National Cancer Institute gives approximately 4.3 new cases per million people.
  • Metastatic disease: IDEAYA estimates an annual incidence of newly diagnosed metastatic uveal melanoma of approximately 1,500 in the United States and 4,000 to 5,000 globally, based on data suggesting that approximately 50% of patients diagnosed in the primary setting progress to metastatic disease. Published estimates of the share of patients who develop metastases are up to 50% and 40% or more; after treatment for choroidal melanoma, 5- and 10-year cumulative metastasis rates were 25% (95% CI, 23% to 27%) and 34% (95% CI, 32% to 37%).
  • HLA-A∗02:01 status: IDEAYA states that HLA∗A2(-) patients represent “between 60-65% of all mUM patients” and that loss of heterozygosity could lead to over-reporting of HLA∗A2(+) prevalence in blood-based testing. HLA-A∗02:01-negative patients comprised 49% of individuals prescreened for a trial of tebentafusp. In a U.S. real-world cohort of 219 participants with metastatic uveal melanoma (Tempus database, 2019-2025), HLA-A∗02:01 status was positive in 42.0%, negative in 42.9%, and unknown in 15.1%. Published articles state that HLA-A∗02:01-positive individuals account for 45% (or ~45%) of people in the United States and Europe, and that 40–50% of the European population express HLA-A∗02:01.
  • Eligibility for tebentafusp: IDEAYA's presentation states “< 50% patients eligible for the only approved systemic therapy”, and Delcath states “Currently 55% of the patients are not eligible for KIMMTRAK”.

Summary: health technology assessments and cost-effectiveness analyses of tebentafusp

  • NICE recommends tebentafusp for HLA-A∗02:01-positive unresectable or metastatic uveal melanoma only with the company's commercial arrangement; the list price is £10,114 per 200 microgram vial. The company's 3-state partitioned survival model used a starting age of 62 years, a 38-year time horizon, utility values by time to death, and the costs of HLA-A∗02:01 testing. With the end-of-life criteria, the acceptable ICER was around £39,000 per QALY gained; the ICERs are confidential. The resource impact report projects 120 to 125 people eligible each year, uptake of 25% in 2025-26 and 50% thereafter, and 60 people having tebentafusp each year from 2026-27, with pembrolizumab as the other treatment.
  • The Scottish Medicines Consortium accepted tebentafusp for use within NHSScotland in the context of a Patient Access Scheme; the company's economic analysis used a partitioned survival model against pembrolizumab and nivolumab plus ipilimumab; the cost per year at list price is £525,928, and results in the pembrolizumab comparison showed a less favourable economic case.
  • CADTH: at the sponsor-submitted price of $18,565 per vial, tebentafusp costs approximately $74,260 per 28-day cycle, and the ICER was $728,513 per QALY gained compared with investigator's choice of therapy; a price reduction of 91% would be required to reach $50,000 per QALY. In the CADTH base case, total costs and QALYs were $1,062,137 and 2.40 with tebentafusp and $147,736 and 1.14 with investigator's choice, and the ICER against nivolumab plus ipilimumab in previously untreated patients was $722,268 per QALY gained. Approximately 72% of OS and 92% of PFS with tebentafusp were accrued after the trial period by extrapolation. In the budget impact analysis from the perspective of a Canadian public health care payer, the 3-year budget impact for previously untreated patients was $32,731,194, and extending treatment duration by 1.9 months increased it to $77,670,205.
  • In France, the Transparency Committee gave a favourable opinion for reimbursement and rated tebentafusp as providing a “moderate clinical added value (CAV III)”. In Germany, the G-BA found a “Hint for a considerable additional benefit” compared with dacarbazine, ipilimumab, and pembrolizumab, in approximately 100 to 130 eligible patients.
  • A published analysis using a three-state partitioned survival model from the perspective of U.S. payers found an additional 0.47 QALYs (1.19 vs 0.72) and an incremental cost of $444,280 with tebentafusp, for an ICER of $953,230 per QALY against a willingness-to-pay threshold of $200,000 per QALY; tebentafusp became cost-effective at a unit price of $33.768 per µg.
  • No assessment of uveal melanoma by the Institute for Clinical and Economic Review was found.

Summary: liver-directed therapy and revenue estimates

No cost-effectiveness study of radioembolization with yttrium-90 microspheres for uveal melanoma liver metastases was identified by a CADTH rapid response report, and none of chemosaturation by an NHS England evidence summary. Delcath estimates that 800 patients with uveal melanoma liver metastases in the United States and 1,200 in Europe may be eligible for HEPZATO or CHEMOSAT annually, an addressable market of approximately $600 million per year; the J-Code J9248 became effective on April 1, 2024, with transitional pass-through status under the Outpatient Prospective Payment System expiring on March 31, 2027. Truist analysts project around $800 million in peak revenue for darovasertib in first-line HLA-A2(-) metastatic uveal melanoma, and a second analyst estimate quoted by BioSpace is $415 million in peak revenues in the HLA-A∗02:01-negative population; Leerink notes that darovasertib could compete with KIMMTRAK in HLA-A∗02:01-positive uveal melanoma, an indication IDEAYA also intends to pursue.

Budget impact model or cost-effectiveness analysis of darovasertib plus crizotinib

No evidence found.

Darovasertib price

No evidence found.

Company estimate of the annual incidence of primary and metastatic uveal melanoma and the HLA∗A2(-) share

Manufacturer-published United States list prices of nivolumab, ipilimumab, dacarbazine, and the HEPZATO KIT

No evidence found.

Added benefit and target population of tebentafusp in the German benefit assessment

ItemQuoted record
Extent and probability of the additional benefit of tebentafusp compared to dacarbazine, ipilimumab and pembrolizumab“Hint for a considerable additional benefit”
Number of HLA-A∗02:01-positive adult patients with unresectable or metastatic uveal melanoma eligible for treatment in Germany“approx. 100 - 130 patients”

NICE cost-effectiveness model structure, utilities, and testing costs for tebentafusp

“The company presented a 3‑state partitioned survival model to estimate the cost effectiveness of tebentafusp compared with the usual treatments. The 3 health states were progression-free, progressed-disease and death. The starting age in the model was 62 years, in line with the mean age in the clinical trial (see section 3.5). A time horizon of 38 years, equating to a lifetime, was used.” (opens the source at this quote in a new tab)

“So, it used a time-to-death approach to calculate utility values in its model, which categorises utility based on the length of time before death.” (opens the source at this quote in a new tab)

“So, it used the utility values from NICE's technology appraisal guidance on pembrolizumab for advanced melanoma not previously treated with ipilimumab.” (opens the source at this quote in a new tab)

“It concluded that the time-to-death approach is not consistent with a model structure designed to reflect health-state utilities. But the choice of approach to estimate utility values was unlikely to be an important driver of the cost-effectiveness results.” (opens the source at this quote in a new tab)

“The company included the costs of HLA‑A*02:01 testing in its model. The committee agreed that it was appropriate to include the costs of testing in the model and that this would be simple to adopt in practice.” (opens the source at this quote in a new tab)

“The committee concluded that it was not appropriate to include a stopping rule in the model because the clinical rationale for it had not been adequately justified. After consultation, the company updated its base case to remove the 2‑year stopping rule.” (opens the source at this quote in a new tab)

Scottish Medicines Consortium advice, economic model, and annual list-price cost of tebentafusp

“tebentafusp (Kimmtrak®) is accepted for use within NHSScotland.” (opens the source at this quote in a new tab)

“This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.” (opens the source at this quote in a new tab)

“The model was a partitioned survival model with states for pre-progression, progressed disease and death.” (opens the source at this quote in a new tab)

“Two comparators were included, pembrolizumab and nivolumab plus ipilimumab.” (opens the source at this quote in a new tab)

“Time to death utility values were used in the base case. The utility value for patients with 360 days or more before time to death was derived from the EQ-5D-5L data from IMCgp100-202.” (opens the source at this quote in a new tab)

“Medicines costs included drug acquisition costs, administration costs and subsequent treatment costs, health state costs, and the cost of adverse events.” (opens the source at this quote in a new tab)

“SMC considered results for decision-making that took into account all relevant PAS. SMC is unable to present these results due to competition law issues. Across the base case and scenario analyses, results in the pembrolizumab comparison showed a less favourable economic case.” (opens the source at this quote in a new tab)

“In addition, as tebentafusp is an orphan medicine, SMC can accept greater uncertainty in the economic case.” (opens the source at this quote in a new tab)

CADTH cost-effectiveness estimate, required price reduction, and cost per cycle of tebentafusp

“Treatment with Kimmtrak is expected to cost approximately $74,260 per 28-day cycle.” (opens the source at this quote in a new tab)

“Using the sponsor submitted price for tebentafusp and publicly listed prices for all other drug costs, the incremental cost-effectiveness ratio (ICER) for tebentafusp was $728,513 per quality-adjusted life-year (QALY) gained compared with investigator’s choice of therapy.” (opens the source at this quote in a new tab)

“A price reduction of 91% would be required for tebentafusp to achieve an ICER of $50,000 per QALY gained compared to investigator’s choice of therapy. Given the high degree of uncertainty in the long-term efficacy of tebentafusp, a higher price reduction may be warranted.” (opens the source at this quote in a new tab)

“Approximately 72% of OS and 92% of PFS associated with tebentafusp treatment were accrued after the trial period and based on extrapolation of the OS and PFS curves.” (opens the source at this quote in a new tab)

“The potential drug acquisition cost per patient is high. The health system resource use for tebentafusp is considerable relative to comparators.” (opens the source at this quote in a new tab)

“Drug wastage is quite significant as the standard dose is considerably less than the vial size (68 mcg vs 100 mcg) and single vial use is recommended.” (opens the source at this quote in a new tab)

CADTH appraisal of the sponsor cost-utility model: comparator costs, structure, and health utilities

“At the submitted price of $18,565 per vial, the cost of tebentafusp was $18,565 per week.” (opens the source at this quote in a new tab)

“In estimating the cost of IC of therapy, the sponsor weighted cost by the distribution of treatments used in the control arm of Study 202, which was 12.7% for ipilimumab, 81.7% for pembrolizumab, and 5.6% for chemotherapy with dacarbazine.” (opens the source at this quote in a new tab)

“This resulted in a per cycle cost of $10,375 for the first 4 doses and $6,876 for subsequent doses.” (opens the source at this quote in a new tab)

“The sponsor submitted a partitioned survival model that included 3 health states: preprogression, postprogression, and death (Appendix 3).” (opens the source at this quote in a new tab)

“Health utility declined by 0.084 after treatment discontinuation, reflecting patient preferences collected using the 5-Level EQ-5D instrument in Study 202. The sponsor could not identify any published literature on health utility data in patients with mUM or on modelled health utility for preprogression and postprogression states.” (opens the source at this quote in a new tab)

“In the CADTH base case, tebentafusp was associated with estimated total costs and QALYs of $1,062,137 and 2.40, compared with total costs and QALYs of $147,736 and 1.14 for patients receiving IC of therapy.” (opens the source at this quote in a new tab)

“CADTH conducted a scenario analysis in the previously untreated population and found that tebentafusp was associated with an ICER of $722,268 per QALY gained when compared with nivolumab plus ipilimumab combination therapy.” (opens the source at this quote in a new tab)

CADTH appraisal of the sponsor budget impact analysis: treatment duration, market share, and 3-year budget impact

“The analysis was done from the perspective of a Canadian public health care payer over a 3-year time horizon (2023 to 2025).” (opens the source at this quote in a new tab)

“The sponsor estimated the population size using an epidemiology-based approach, with data obtained from published literature to estimate the number of patients eligible for treatment with tebentafusp.” (opens the source at this quote in a new tab)

“The sponsor estimated the duration of treatment with tebentafusp is twice as much as the comparators. The sponsor assumed no drug wastage in estimating treatment costs.” (opens the source at this quote in a new tab)

“In estimating the drug cost of tebentafusp, the sponsor adopted the median treatment duration of 8 cycles (24 doses) using data from IMCgp100-202 trial.” (opens the source at this quote in a new tab)

“In the IMCgp100-202 trial, treatment with tebentafusp was continued beyond initial progression for nearly half (43.3%) of the patients in the intervention arm. The median duration of treatment postdisease progression was 1.9 months for these patients.” (opens the source at this quote in a new tab)

“In CADTH reanalysis, the market share of tebentafusp was increased to 86% in year 1 and 2 in previously untreated patients.” (opens the source at this quote in a new tab)

“For previously untreated patients, the 3-year budget impact was estimated to be $32,731,194 (Year 1: $10,613,612; Year 2: $10,909,080; Year 3: $11,208,502).” (opens the source at this quote in a new tab)

“The results were sensitive to uncertainty in treatment duration of tebentafusp. Extending treatment duration of tebentafusp by 1.9 months increased the estimated 3-year total budget impact to $77,670,205.” (opens the source at this quote in a new tab)

Institute for Clinical and Economic Review assessment in uveal melanoma

No evidence found.

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.